TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance

Go back to TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance

TransMedics Group (TMDX) PT Lowered to $125 at Oppenheimer

October 29, 2024 6:04 AM EDT

Oppenheimer analyst Suraj Kalia lowered the price target on TransMedics Group (NASDAQ: TMDX) to $125.00 (from $200.00) while maintaining a Outperform rating.

The analyst comments "TransMedics reported 3Q24 revs. of $108.8M, below our/consensus $117.1M/$115.0M estimates. In Q3, our calculated US transplant shares were 21%/27%/4%... More